Poxel's First Quarter 2025 Revenue and Business Developments

Poxel SA reported its consolidated revenue for the first quarter of 2025, marking significant progress in its commercial and regulatory activities. TWYMEEG® consolidated gross sales for Sumitomo Pharma fiscal year 2024 totaled JPY 7.6 billion (EUR 47.2 million), aligning with the company's guidance. Looking ahead, Sumitomo Pharma forecasts a 47% increase in TWYMEEG® sales for fiscal year 2025. This optimism is supported by the recent approval for TWYMEEG® to be used in Japanese patients with renal impairment.

Poxel is set to receive increasing royalties from TWYMEEG® sales, with expectations of double-digit percentages and additional payments upon meeting sales thresholds. The company continues to work with creditors to ensure operational continuity and seeks partners for further pipeline development. Revenue for the first quarter reached EUR 1,066 thousand, a 137% increase compared to last year's Q1, reflecting royalty income primarily from TWYMEEG® sales.